Waters Corporation(WAT)

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest News & Analysis
Waters Corporation (WAT): Biopharma Focus, Emerging Markets, and Financial Outlook
Waters Corporation navigates biopharma growth, emerging markets, and FX headwinds. Strategic HPLC innovations and Indian expansion face valuation and currency challenges.
Waters Corporation Innovates with HPLC Expansion
Waters Corporation’s HPLC expansion and strong Q4 performance underscore its growth in biopharma and diagnostics.
Waters Corporation (WAT) Q4 2024: Growth, Valuation, and Market Trends
Waters Corporation's Q4 2024 results show strong growth, driven by pharma and emerging markets. Valuation concerns persist despite innovation in material testing.
Waters Corporation: Growth Opportunities and Valuation Challenges
Waters Corporation navigates growth amid valuation concerns, focusing on pharma, India, PFAS & GLP-1. Investor Day 2025 key.
Waters Corporation (WAT): Analyzing Q4 2024 Results, 2025 Growth Outlook, and Investor Day Preview
Waters Corporation (WAT) reported strong Q4 2024 results, with revenue exceeding guidance. The 2025 outlook is positive, driven by growth in pharma, emerging markets, and innovative products. However, valuation concerns and FX headwinds persist.
Waters Corporation: Q4 Earnings, Growth Drivers & Investor Day Preview
Waters Corporation's Q4 earnings beat estimates, driven by pharma and academia growth. Upcoming Investor Day and ElectroForce Apex 1 launch are key focuses.
Waters Corporation (WAT): Q4 2024 Results, Market Trends, and Future Outlook
Waters Corporation (WAT) demonstrates strong Q4 2024 results, driven by pharma, academia, and government sectors. Valuation and forex remain key concerns.
Waters Corporation (WAT): Growth Amidst Valuation Concerns
Waters Corporation navigates growth amidst valuation concerns, fueled by GLP-1 & PFAS testing. Investor Day preview, FX headwinds, and analyst outlook analyzed.
Waters Corporation Q4 2024 Earnings Analysis: Growth Momentum, Valuation Concerns
Waters Corporation delivered robust Q4 2024 results with strong growth in pharma and academia, though FX and valuation concerns persist.